Nicotinic receptor modulation to treat alcohol and drug dependence

Shafiqur Rahman, Eric Engleman, Richard Bell

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Alcohol and drug dependence are serious public health problems worldwide. The prevalence of alcohol and drug dependence in the United States and other parts of the world is significant. Given the limitations in the efficacy of current pharmacotherapies to treat these disorders, research in developing alternative pharmacotherapies continues. Preclinical and clinical evidence thus far has indicated that brain nicotinic acetylcholine receptors (nAChRs) are important pharmacological targets for the development of medications to treat alcohol and drug dependence. The nAChRs are a super family of ligand gated ion channels, and are expressed throughout the brain with twelve neuronal nAChR subunits (a2-a10 and β2-β4) identified. Here, we review preclinical and clinical evidence involving a number of nAChR ligands that target different nAChR subtypes in alcohol and nicotine addiction. The important ligands include cytisine, lobeline, mecamylamine, varenicline, sazetidine A and others that target a4β2* nAChR subtypes as small molecule modulators of the brain nicotinic cholinergic system are also discussed. Taken together, both preclinical and clinical data exist that support nAChR-based ligands as promising therapeutic agents for the treatment of alcohol and drug dependence.

Original languageEnglish
Article number426
JournalFrontiers in Neuroscience
Volume9
Issue numberJAN
DOIs
StatePublished - 2015

Fingerprint

Nicotinic Receptors
Alcoholism
Substance-Related Disorders
Ligands
Brain
Lobeline
Ligand-Gated Ion Channels
Mecamylamine
Drug Therapy
Nicotine
Cholinergic Agents
Public Health
Pharmacology
Therapeutics
Research

Keywords

  • Alcohol dependence
  • Animal models
  • CNS disorders
  • Drug addiction
  • Drug development
  • Nicotine addiction
  • Nicotinic receptor

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Nicotinic receptor modulation to treat alcohol and drug dependence. / Rahman, Shafiqur; Engleman, Eric; Bell, Richard.

In: Frontiers in Neuroscience, Vol. 9, No. JAN, 426, 2015.

Research output: Contribution to journalArticle

@article{4bd784dacb1a45459dcb7dd225c6e9a3,
title = "Nicotinic receptor modulation to treat alcohol and drug dependence",
abstract = "Alcohol and drug dependence are serious public health problems worldwide. The prevalence of alcohol and drug dependence in the United States and other parts of the world is significant. Given the limitations in the efficacy of current pharmacotherapies to treat these disorders, research in developing alternative pharmacotherapies continues. Preclinical and clinical evidence thus far has indicated that brain nicotinic acetylcholine receptors (nAChRs) are important pharmacological targets for the development of medications to treat alcohol and drug dependence. The nAChRs are a super family of ligand gated ion channels, and are expressed throughout the brain with twelve neuronal nAChR subunits (a2-a10 and β2-β4) identified. Here, we review preclinical and clinical evidence involving a number of nAChR ligands that target different nAChR subtypes in alcohol and nicotine addiction. The important ligands include cytisine, lobeline, mecamylamine, varenicline, sazetidine A and others that target a4β2* nAChR subtypes as small molecule modulators of the brain nicotinic cholinergic system are also discussed. Taken together, both preclinical and clinical data exist that support nAChR-based ligands as promising therapeutic agents for the treatment of alcohol and drug dependence.",
keywords = "Alcohol dependence, Animal models, CNS disorders, Drug addiction, Drug development, Nicotine addiction, Nicotinic receptor",
author = "Shafiqur Rahman and Eric Engleman and Richard Bell",
year = "2015",
doi = "10.3389/fnins.2014.00426",
language = "English",
volume = "9",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",
number = "JAN",

}

TY - JOUR

T1 - Nicotinic receptor modulation to treat alcohol and drug dependence

AU - Rahman, Shafiqur

AU - Engleman, Eric

AU - Bell, Richard

PY - 2015

Y1 - 2015

N2 - Alcohol and drug dependence are serious public health problems worldwide. The prevalence of alcohol and drug dependence in the United States and other parts of the world is significant. Given the limitations in the efficacy of current pharmacotherapies to treat these disorders, research in developing alternative pharmacotherapies continues. Preclinical and clinical evidence thus far has indicated that brain nicotinic acetylcholine receptors (nAChRs) are important pharmacological targets for the development of medications to treat alcohol and drug dependence. The nAChRs are a super family of ligand gated ion channels, and are expressed throughout the brain with twelve neuronal nAChR subunits (a2-a10 and β2-β4) identified. Here, we review preclinical and clinical evidence involving a number of nAChR ligands that target different nAChR subtypes in alcohol and nicotine addiction. The important ligands include cytisine, lobeline, mecamylamine, varenicline, sazetidine A and others that target a4β2* nAChR subtypes as small molecule modulators of the brain nicotinic cholinergic system are also discussed. Taken together, both preclinical and clinical data exist that support nAChR-based ligands as promising therapeutic agents for the treatment of alcohol and drug dependence.

AB - Alcohol and drug dependence are serious public health problems worldwide. The prevalence of alcohol and drug dependence in the United States and other parts of the world is significant. Given the limitations in the efficacy of current pharmacotherapies to treat these disorders, research in developing alternative pharmacotherapies continues. Preclinical and clinical evidence thus far has indicated that brain nicotinic acetylcholine receptors (nAChRs) are important pharmacological targets for the development of medications to treat alcohol and drug dependence. The nAChRs are a super family of ligand gated ion channels, and are expressed throughout the brain with twelve neuronal nAChR subunits (a2-a10 and β2-β4) identified. Here, we review preclinical and clinical evidence involving a number of nAChR ligands that target different nAChR subtypes in alcohol and nicotine addiction. The important ligands include cytisine, lobeline, mecamylamine, varenicline, sazetidine A and others that target a4β2* nAChR subtypes as small molecule modulators of the brain nicotinic cholinergic system are also discussed. Taken together, both preclinical and clinical data exist that support nAChR-based ligands as promising therapeutic agents for the treatment of alcohol and drug dependence.

KW - Alcohol dependence

KW - Animal models

KW - CNS disorders

KW - Drug addiction

KW - Drug development

KW - Nicotine addiction

KW - Nicotinic receptor

UR - http://www.scopus.com/inward/record.url?scp=84921726483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921726483&partnerID=8YFLogxK

U2 - 10.3389/fnins.2014.00426

DO - 10.3389/fnins.2014.00426

M3 - Article

AN - SCOPUS:84921726483

VL - 9

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

IS - JAN

M1 - 426

ER -